Citigroup Inc Gemini Therapeutics, Inc. Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$1.31 - $2.01 $290 - $446	-222 Reduced 0.43%	50,871 $83,000
Q2 2022 Aug 10, 2022	BUY	$1.22 - $1.73 $61,213 - $86,802	50,175 Added 5465.69%	51,093 $86,000
Q1 2022 May 12, 2022	SELL	$1.29 - $3.08 $6,012 - $14,355	-4,661 Reduced 83.55%	918 $1,000
Q4 2021 Feb 10, 2022	BUY	$2.39 - $4.0 $7,368 - $12,332	3,083 Added 123.52%	5,579 $16,000
Q3 2021 Nov 10, 2021	BUY	$3.3 - $6.32 $8,236 - $15,774	2,496 New	2,496 $10,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.